Related Experiment Video
Updated: Aug 3, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Percutaneous left atrial appendage closure for stroke prevention in patients with chronic renal disease
Alexander Lind1, Obayda Azizy1, Julia Lortz1
1Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Essen, Germany.
Insights
Left atrial appendage closure (LAAC) is a safe and effective stroke prevention method for patients with atrial fibrillation (AF) and chronic kidney disease (CKD). This procedure demonstrates feasibility and success even in patients with moderate to severe CKD.
Area of Science:
- Cardiology
- Nephrology
Background:
- Atrial fibrillation (AF) is a common arrhythmia linked to increased stroke risk.
- Chronic kidney disease (CKD) elevates stroke and mortality risk in AF patients.
- Left atrial appendage closure (LAAC) is an alternative stroke prevention for AF patients with bleeding risks.
Purpose of the Study:
- To assess the safety and feasibility of percutaneous LAAC in patients with CKD.
- To evaluate outcomes of LAAC in AF patients stratified by CKD severity.
Main Methods:
- An observational, single-center study included 97 AF patients undergoing LAAC.
- Patients were categorized into mild (KDOQI I-II) and moderate-to-severe (KDOQI III-V) CKD groups.
- Outcomes included procedural success, occlusion, stroke prevention, and bleeding complications.
Main Results:
- Patients with moderate-to-severe CKD had higher thromboembolic and bleeding risk scores (CHA2DS2-VASc, HAS-BLED).
- Procedural and occlusion success rates were similar between CKD groups (97.9% vs. 95.9%).
- Effective stroke prevention and no bleeding complications were observed at 6-36 months follow-up in both groups.
Conclusions:
- Percutaneous LAAC is a safe and feasible stroke prevention strategy for AF patients with CKD.
- The procedure is effective regardless of CKD severity, offering a viable option for high-risk patients.
Introduction:
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population. Atrial fibrillation is associated with an increased risk of thromboembolic events, particularly stroke. Chronic kidney disease (CKD) is associated with a higher prevalence of AF and is an independent risk factor of increased mortality and stroke in AF patients. Left atrial appendage closure (LAAC) for stroke prevention plays an important role in the treatment of patients with AF and increased bleeding risk. The impact of CKD on outcomes after LAAC has not been deeply investigated. We assessed whether percutaneous LAAC is safe and feasible in CKD patients.
Material And Methods:
Ninety-seven patients (mean age: 73.9 ±8.5 years) with AF and contraindications for oral anticoagulation (OAC) or complications under OAC underwent LAAC with the Amplatzer Cardiac Plug and the Amplatzer Amulet Occluder in an open-label observational single-center study. We classified patients as having normal to mild (KDOQI stage I-II) or moderate to severe (KDOQI stage III-V) CKD.
Results:
Patients with moderate to severe CKD (n = 49) had increased CHA2DS2-VASc and HAS-BLED scores and were at higher thromboembolic and bleeding risk (CHA2DS2-VASc: 4.08 ±0.79, HAS-BLED: 4.76 ±0.69) than patients with mild to moderate CKD (n = 48, CHA2DS2-VASc: 3.69 ±1.1, HAS-BLED: 4.06 ±0.66; p < 0.001 for both). In both groups, procedural and occlusion success was similar (97.9% vs. 95.9%; p = 0.479). Follow-up of 6 months and from 12 to 36 months revealed effective stroke prevention and no bleeding complication in both groups.
Conclusions:
In spite of a higher thromboembolic and bleeding risk in patients with severe CKD, LAAC is a safe and feasible option for stroke prevention.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Hemodialysis I: Introduction
Acute Kidney Injury V: Interprofessional Care

